CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended Shareholders vote “FOR” all the proposed resolutions at the upcoming Annual and Special Meeting of Shareholders (the “Meeting”) to be held on September 12, 2024.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Fisher House Dedicated in Memphis, Tennessee - September 17, 2024
- ROSEN, A LEADING LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM - September 17, 2024
- BOOZ ALLEN PARTNERS WITH AMERICA’S VETDOGS TO SPONSOR AND RAISE A SERVICE DOG IN TRAINING - September 17, 2024
